오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 2.5 mg - tablet - excipient ingredients: lactose; hypromellose; triacetin; croscarmellose sodium; titanium dioxide; iron oxide yellow; magnesium stearate; microcrystalline cellulose; purified talc; poloxamer; sodium lauryl sulfate - tadalafil-dr.reddy's is indicated for the treatment of:,? erectile dysfunction (ed) in adult males,? moderate to severe lower urinary tract symptoms (luts) associated with benign prostatic hyperplasia (bph) in adult males.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - tadalafil, quantity: 10 mg - tablet - excipient ingredients: magnesium stearate; triacetin; croscarmellose sodium; titanium dioxide; microcrystalline cellulose; iron oxide yellow; poloxamer; sodium lauryl sulfate; hypromellose; lactose; purified talc - tadalafil-dr.reddy?s is indicated for the treatment of:,? erectile dysfunction (ed) in adult males.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carboprost trometamol, quantity: 332 microgram (equivalent: carboprost, qty 250 microgram) - injection, solution - excipient ingredients: trometamol; water for injections; benzyl alcohol; sodium chloride; sodium hydroxide; hydrochloric acid - carboprost dr.reddy?s is indicated for the treatment of postpartum haemorrhage due to uterine atony which has not responded to conventional methods of management.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - cabazitaxel, quantity: 60 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid - cabazitaxel dr.reddy?s in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - carmustine, quantity: 100 mg - injection, diluent for - excipient ingredients: ethanol absolute - carmustine dr.reddy's is indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in the following: 1. malignant glioma 2. multiple myeloma - in combination with prednisone. 3. hodgkin?s disease - as secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy. 4. non-hodgkin?s lymphomas - as secondary therapy in combination with other approved drugs for patients who relapse while being treated with primary therapy or who fail to respond to primary therapy.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddy's laboratories australia pty ltd - irbesartan -

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: lactose monohydrate; meglumine; crospovidone; microcrystalline cellulose; magnesium stearate; titanium dioxide; indigo carmine aluminium lake; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,- prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,- in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic s

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium, quantity: 5.2 mg - tablet, film coated - excipient ingredients: meglumine; magnesium stearate; crospovidone; microcrystalline cellulose; lactose monohydrate; titanium dioxide; indigo carmine aluminium lake; hypromellose; triacetin; allura red ac aluminium lake; quinoline yellow aluminium lake - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,- prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,- in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic s

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium, quantity: 10.4 mg - tablet, film coated - excipient ingredients: meglumine; lactose monohydrate; microcrystalline cellulose; crospovidone; magnesium stearate; titanium dioxide; indigo carmine aluminium lake; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,- prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,- in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic s

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: crospovidone; lactose monohydrate; microcrystalline cellulose; magnesium stearate; meglumine; titanium dioxide; indigo carmine aluminium lake; hypromellose; sunset yellow fcf aluminium lake; triacetin; allura red ac aluminium lake - rosuvastatin should be used as an adjunct to diet when the response to diet and exercise is inadequate.,- prevention of cardiovascular events,rosuvastatin is indicated for prevention of major cardiovascular events in men greater than or equal to 50 years old and women greater than or equal to 60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin is indicated to:,? reduce the risk of nonfatal myocardial infarction,? reduce the risk of nonfatal stroke,? reduce the risk of coronary artery revascularisation procedures.,- in patients with hypercholesterolaemia,rosuvastatin is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia).,prior to initiating therapy with rosuvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic s